Embedded Files
Tofacitinib 1,010 (1.7) Nonbiologic DMARDs‡ 40,272 (66.7) Methotrexate 26,278 (43.5) Hydroxychloroquine 14,051 (23.3) Leflunomide 5,136 (8.5) Azathioprine 860 (1.4) Sulfasalazine 3,348 (5.6) Minocycline 271 (0.5) Cyclosporine 34 (0.05) Penicillamine 6 (0.01) Cyclophosphamide 12 (0.02) Gold 16 (0.03) Prednisone 19,073 (31.6) * Values are the number (percentage). RISE 5 Rheumatology Informatics System for Effectiveness; DMARD 5 disease-modifying antirheumatic drug; TNF 5 tumor necrosis factor. † Medications in the biologic agent category are mutually exclusive; in other words, algorithms were constructed to ensure patients were only counted once in these categories. In cases where more than 1 medication was listed as active at the last encounter, we constructed algorithms to select 1 drug. ‡ For nonbiologic DMARDs, the overall percentage of 66.7 reflects the patients that were on any nonbiologic drug. The percentages using specific drugs listed below this in the Table are not mutually exclusive; in other words, patients might be represented twice. Using RISE Registry to Improve Quality of Care 1871 Table 4. Performance on selected quality measures in the RISE registry* Quality measure Measure denominator, no. Measure numerator, no. Performance, % RA: assessment of disease activity (NQF 2523): patients age $18 years with a diagnosis of RA and $50% of total number of outpatient encounters in the measurement year with assessment of disease activity using a standardized measure 58,095 32,087 55.2 RA: functional status assessment (NQF 2524): patients age $18 years with a diagnosis of RA for whom a functional status assessment was performed at least once during the measurement period 58,095 31,127 53.6 RA: DMARD therapy (NQF 2525): patients age $18 years with a diagnosis of RA who are prescribed DMARD therapy within 12 months 57,893 52,670 91.0 Drug safety: TB screening prior to first biologic agent therapy (NQF 2522): patients age $18 years with a diagnosis of RA who have documentation of a TB screening performed within 12 months prior to receiving a first course of therapy using a biologic DMARD 17,341 9,570 55.2 Drug safety: use of high-risk medications in the elderly: patients age $66 years who received at least 1 high-risk medication 98,606 3,880 3.9† Drug safety: patients age $66 years who received at least 2 different high-risk medications 98,606 121 0.12† Osteoporosis: female patients age $65 years who have a central DXA measurement ordered or performed at least once since age 60 years or pharmacologic therapy prescribed within 12 months 77,900 45,472 58.4 Osteoporosis: patients age $18 years with 1 of the following conditions or therapies: receiving oral glucocorticoid therapy for greater than 3 months OR hypogonadism OR fracture history OR transplant history OR obesity surgery OR malabsorption disease OR receiving aromatase therapy for breast cancer who had a central DXA ordered or performed or pharmacologic therapy prescribed within 12 months 52,966 32,388 61.2 Osteoporosis: patients age $50 years with fracture of the hip, spine, or distal radius who had a central DXA measurement ordered or performed or pharmacologic therapy prescribed 7,496 3,840 51.2 Low back pain: patients with a primary diagnosis of low back pain who did not have an imaging study (plain radiograph, MRI, CT scan) within 28 days of the diagnosis 16,239 11,389 70.1 Preventive care and screening: patients age $18 years who were screened for tobacco use $1 time within 24 months AND who received cessation counseling intervention if identified as a tobacco user 260,384 213,646 82.1 Preventive care and
Report abuse